Susan Molineaux - 17 Jun 2021 Form 3 Insider Report for Cyteir Therapeutics, Inc.

Role
Director
Signature
By: /s/ Andrew Gengos, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
17 Jun 2021
Net transactions value
$0
Form type
3
Filing time
17 Jun 2021, 21:32:45 UTC
Previous filing
13 May 2021
Next filing
10 Nov 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CYT Stock Option (Right to Buy) 17 Jun 2021 Common Stock 44,003 $1.67 Direct F1
holding CYT Stock Option (Right to Buy) 17 Jun 2021 Common Stock 16,424 $7.09 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will become exercisable as to 1/36th of the underlying shares of common stock at the end of each successive one-month period following the vesting commencement date, December 9, 2020, until the option is fully vested on the third anniversary of the vesting commencement date, subject to the Reporting Person's continued service on the Issuer's board of directors through the applicable vesting date.
F2 The option will become exercisable as to 1/36th of the underlying shares of common stock at the end of each successive one-month period following the vesting commencement date, February 5, 2021, until the option is fully vested on the third anniversary of the vesting commencement date, subject to the Reporting Person's continued service on the Issuer's board of directors through the applicable vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney